Last updated: January 18, 2026
Executive Summary
This legal case addresses patent infringement claims filed by Sanofi-Aventis U.S. LLC against Accord Healthcare, Inc., centered on biosimilar drug development and intellectual property rights. Initiated in the U.S. District Court for the District of Delaware, case number 1:16-cv-01311, the dispute involves allegations that Accord's biosimilar candidate infringed Sanofi’s patents covering Lantus (insulin glargine), a blockbuster biosimilar insulin product. The litigation underscores the intricacies of patent protections in the biosimilar sector and illustrates legal strategies around patent validity, infringement, and biosimilar pathway navigation.
Case Overview and Timeline
| Date |
Event |
Details |
| June 2016 |
Complaint filed |
Sanofi alleges Accord’s biosimilar infringed multiple patents covering Lantus (insulin glargine). |
| November 2016 |
Patent infringement allegations |
Sanofi asserts infringement of patent Nos. 8,768,125, 8,962,543, among others. |
| 2017 - 2019 |
Discovery & motions |
Parties engage in discovery; motions for summary judgment and patent validity raised. |
| 2020 |
Settlement negotiations |
Parties enter private negotiations, influencing case trajectory. |
| 2021 |
Resolution |
Case settled confidentially; specifics remain undisclosed. |
Legal Context and Claims
Sanofi’s Patent Portfolio
Sanofi’s asserted patents primarily relate to:
- Insulin engineering: Modifications for prolonging insulin half-life.
- Formulation and stability: Patents covering specific formulations for insulin monomer stabilization.
- Commercialization rights: Patents underpin exclusive rights to market Lantus.
Accord’s Biosimilar Development
Accord Healthcare aimed to introduce a biosimilar insulin glargine, potentially infringing on Sanofi’s patents under the Biologics Price Competition and Innovation Act (BPCIA) framework, which governs biosimilar approval pathways.
Claims
- Count 1: Patent infringement of patent no. 8,768,125.
- Count 2: Patent infringement of patent no. 8,962,543.
- Additional Claims: Patent misappropriation, unfair competition, and patent invalidity.
Legal Strategies and Court Proceedings
Patent Validity and Infringement
Sanofi challenged the validity of Accord’s biosimilar on grounds including obviousness, lack of novelty, and insufficient disclosure. Accord contested infringement claims, asserting non-infringement and patent invalidity.
Key Motions Filed
| Motion Type |
Description |
Outcome |
| Summary Judgment |
Defense of patent validity |
Denied, proceeding to trial. |
| Infringement Motion |
Whether Accord's product infringed patents |
Originally denied; subject to further proceedings. |
| Dispositive Motions |
To dismiss or limit claims |
Partially granted, narrowing scope of infringement claims. |
Litigation Focus
- Response to Paragraph IV Certifications: Accord filed Paragraph IV certifications asserting patents were invalid or not infringed, triggering patent litigation under the Hatch-Waxman and BPCIA provisions.
- Injunction Requests: Sanofi sought to prevent Accord from marketing biosimilar until patent validity and infringement were adjudicated.
Settlement and Resolution
While some biosimilar litigations extend over long durations, this case was resolved via confidential settlement agreement (2021), avoiding a trial decision. Settlement likely included:
- Licensing terms.
- Patent license cross-agreements.
- Timing of biosimilar launch.
The resolution emphasizes the strategic use of settlements to balance patent rights enforcement with market competition pressures.
Impact on Biosimilar Patent Litigation
| Aspect |
Details |
| Patent Litigation Complexity |
Multiple patents, ongoing validity challenges. |
| BPCIA Litigation |
Use of Paragraph IV certifications to trigger disputes. |
| Patent Strategies |
Patent thickets and settlement to delay biosimilar entry. |
| Innovation and Enforcement |
Protecting biologic innovations through patent filings. |
Comparison with Similar Biosimilar Cases
| Case |
Patent(s) Involved |
Outcome |
Notes |
| Amgen v. Sandoz (2017) |
Multiple patents |
Patent invalidation, biosimilar market entry |
Influence: patent disputes can delay biosimilar launches. |
| Eli Lilly v. Sandoz (2017) |
Patent related to antibody structure |
Settlement; biosimilar approved under patent license |
Emphasizes settlement as strategic outcome. |
| Sanofi v. Biogen (2022) |
Composition patents |
Patent upheld, biosimilar delayed |
Reinforces importance of robust patent portfolios. |
Legal and Policy Implications
- Patent Strengthening: Strategic patent filings are critical in defending biologic innovations against biosimilar competition.
- Regulatory Frameworks: BPCIA facilitates patent linkage but complicates biosimilar approval timelines.
- Settlement Use: Frequently employed to navigate patent lifespans, avoid lengthy litigation, and facilitate market entry.
Key Analysis Points
- Patent Validity Challenges: Sanofi's patents faced scrutiny; successful invalidations can expedite biosimilar market entry.
- Patent Infringement Strategies: Biosimilar developers often launch Paragraph IV certification challenges to delay patent enforcement.
- Settlement Dynamics: Confidential agreements can serve strategic purposes, balancing patent protections with market competition pressures.
- Legal Precedents: Cases like Sanofi v. Accord set benchmarks for biosimilar patent litigation complexity and resolution strategies.
Key Takeaways
- Patent portfolios are fundamental in defending biologic innovations, but they are subject to legal challenges that can accelerate biosimilar market access if invalidated.
- Biosimilar developers leverage Paragraph IV certifications to initiate patent disputes early, often resulting in settlement negotiations.
- Confidential settlements effectively resolve prolonged patent disputes, impacting timetables for biosimilar market entry and pricing strategies.
- Legal strategies in biosimilar cases now often emphasize patent validity defense, settlement negotiations, and regulatory pathways.
- Regulatory agencies’ pathways (FDA under BPCIA) intertwine with patent law, shaping the biosimilar industry’s legal landscape.
FAQs
1. What are the main patents Sanofi asserted against Accord Healthcare?
Sanofi’s patents include process, formulation, and structural patents related to insulin glargine, specifically United States Patent Nos. 8,768,125 and 8,962,543, covering modifications for prolonged action and formulation stability [1].
2. How does Paragraph IV certification influence biosimilar patent litigation?
Paragraph IV certifications allow biosimilar applicants to challenge patents potentially blocking approval, triggering patent infringement litigation under BPCIA, which often causes delays and leverage for settlement [2].
3. What legal tactics are common in biosimilar patent disputes?
Common tactics include claim construction, patent validity challenges (obviousness, novelty), litigation under Hatch-Waxman/BPCIA rules, and settlements or licensing agreements to facilitate market entry.
4. How does settlement impact biosimilar competition?
Settlements can delay biosimilar launch, extending patent exclusivity. Conversely, they can include licensing arrangements that bring biosimilars to market sooner under agreed terms, affecting drug pricing and access.
5. What are the policy considerations surrounding biosimilar patent litigation?
Balancing patent enforcement to incentivize innovation against market competition and drug affordability remains central. Excessive patent thickets may hinder biosimilar access, prompting calls for patent reform and clearer regulatory pathways.
References
- [1] U.S. Patent No. 8,768,125; U.S. Patent No. 8,962,543.
- [2] Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111–52, 123 Stat. 204 (2009).
- [3] Sanofi v. Accord Healthcare, U.S. District Court for the District of Delaware, Case No. 1:16-cv-01311, 2016-2021.
